- Report
- August 2024
- 150 Pages
Global
From €3409EUR$3,750USD£2,931GBP
- Report
- July 2024
- 150 Pages
Global
From €3409EUR$3,750USD£2,931GBP
- Report
- July 2024
- 150 Pages
Global
From €3409EUR$3,750USD£2,931GBP
- Report
- July 2024
- 100 Pages
Global
From €3409EUR$3,750USD£2,931GBP
- Report
- July 2024
- 100 Pages
Global
From €3409EUR$3,750USD£2,931GBP
- Report
- July 2024
- 100 Pages
Global
From €3409EUR$3,750USD£2,931GBP
- Report
- January 2024
- 174 Pages
Global
From €7226EUR$7,950USD£6,213GBP
- Report
- June 2022
- 320 Pages
Global
From €12635EUR$13,900USD£10,863GBP
- Report
- May 2025
- 84 Pages
United States
From €3181EUR$3,500USD£2,735GBP
- Report
- July 2026
- 80 Pages
Spain
From €4318EUR$4,750USD£3,712GBP
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 61 Pages
Mexico
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 70 Pages
South Africa
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 80 Pages
Saudi Arabia
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 75 Pages
South Korea
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 90 Pages
China
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 69 Pages
United Kingdom
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 120 Pages
Germany
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 69 Pages
Brazil
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 85 Pages
France
From €4318EUR$4,750USD£3,712GBP

Diabetic Retinopathy (DR) is a medical condition that affects the eyes of people with diabetes. It is caused by damage to the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. DR can lead to vision loss and blindness if left untreated.
Optical imaging technologies, such as optical coherence tomography (OCT) and fundus photography, are used to diagnose and monitor DR. These technologies allow for early detection and treatment of DR, which can help to reduce the risk of vision loss.
In addition to imaging technologies, there are a number of treatments available for DR, including laser photocoagulation, intravitreal injections, and vitrectomy. These treatments can help to reduce the risk of vision loss and improve vision in those with DR.
The DR market is a rapidly growing market, driven by the increasing prevalence of diabetes and the need for early detection and treatment of DR.
Companies in the DR market include Carl Zeiss Meditec, Topcon Corporation, Optos, Nidek, and Heidelberg Engineering. Show Less Read more